99% Purity Cartalax CAS 45234-02-4 Raw Peptide Factory Supply High Quality Low Price

WhatsApp +852 9339 8574
Cartalax is a synthetic, short-chain bioactive peptide widely used in *in vitro* cellular research due to its stable molecular structure and targeted cellular regulatory properties. Typically supplied as a high-purity lyophilized powder with consistent physicochemical properties across batches, it serves as a reliable research material for various *in vitro* cell model experiments. Research on Cartalax focuses primarily on regulating chondrocyte activity, promoting extracellular matrix (ECM) synthesis, and balancing matrix metabolism; it is a peptide reagent of significant interest to researchers studying connective tissue cells and ECM-related processes.

Physicochemically, Cartalax lyophilized powder appears as a white to off-white solid and exhibits good solubility in appropriate solvent systems. Researchers can flexibly prepare peptide solutions at various concentrations to suit diverse *in vitro* experimental designs. As a short-chain peptide, it maintains molecular stability over long periods when stored under low-temperature, sealed, and light-protected conditions; this stability slows degradation and ensures a consistent concentration of the active ingredient during experiments. High-purity Cartalax contains 99% or more of the active ingredient, with impurities strictly controlled at minimal levels to reduce interference with cell culture systems. This ensures experimental data reproducibility and reliable reference value, meeting the rigorous purity standards required for various research projects. Each production batch undergoes comprehensive testing, accompanied by a Certificate of Analysis (COA) that clearly documents physicochemical parameters, thereby guaranteeing consistent product quality across batches.

The primary function of Cartalax in *in vitro* cellular systems lies in the regulation of chondrocyte activity and the maintenance of ECM metabolic balance. In relevant *in vitro* models, the peptide acts intracellularly to modulate the expression of genes associated with matrix synthesis and degradation, thereby optimizing the synthesis of ECM components. During continuous in vitro subculture, chondrocyte viability gradually declines, leading to reduced matrix synthesis and increased expression of matrix-degrading enzymes, thereby disrupting the dynamic balance between matrix synthesis and degradation. Cartalax acts on chondrocytes by upregulating the synthesis of matrix components—such as collagen and proteoglycans—while inhibiting the expression of specific matrix-degrading enzymes. By maintaining the structural integrity of the extracellular matrix and delaying functional decline, Cartalax enables cultured chondrocytes to retain their native biological characteristics for extended periods, making it suitable for long-term, continuous cell culture and observation experiments.

Regarding the regulation of the cellular microenvironment, Cartalax optimizes the extracellular milieu of chondrocytes and mitigates cellular damage caused by oxidative products. During in vitro culture, cells continuously generate reactive oxygen species (ROS); excessive ROS can damage intracellular macromolecules—such as proteins and nucleic acids—gradually compromising cellular structure and inhibiting metabolic activities associated with matrix synthesis. Cartalax balances intracellular redox systems by scavenging excess ROS and reducing the adverse effects of oxidative stress. It protects cell membranes and intracellular macromolecular structures, enhances chondrocyte viability, alleviates oxidative inhibition of matrix anabolism, and extends the effective survival period of cells in culture, thereby establishing stable conditions for long-term observation experiments.

Cartalax is primarily utilized in various in vitro cell model experiments, particularly in research concerning chondrocyte viability, extracellular matrix metabolic regulation, and mechanisms of response to oxidative stress. Researchers typically incorporate Cartalax into the culture medium and conduct intervention studies with multiple control groups. By monitoring changes in parameters such as gene expression profiles, cell viability, and matrix protein content, they elucidate the molecular mechanisms through which this peptide regulates chondrocyte function and extracellular matrix homeostasis. This material is also suitable for parallel control experiments involving peptides; it can be tested alongside other peptides in the same category (connective tissue regulators) to investigate the differential effects of various peptides on matrix synthesis and cell survival, thereby continuously enriching the database for fundamental peptide research.

Compared to other research peptides in the same category, Cartalax exhibits distinct functional characteristics. While GHK-Cu regulates various matrix-related active factors and promotes the synthesis of matrix components across a broad range of connective tissue cell types, Cartalax demonstrates a specific affinity for chondrocytes, selectively regulating their metabolism to enhance cartilage matrix synthesis. BPC-157 offers broad-spectrum cytoprotection across diverse cell types, whereas Cartalax focuses its regulatory activity on maintaining the balance of chondrocyte matrix metabolism. TB-500 primarily influences cell migration and maintains connective tissue integrity, while Cartalax focuses on regulating the transcriptional levels of genes associated with matrix synthesis and degradation. Thymosin Alpha-1 regulates cytokine expression and reduces oxidative damage, making it common in immune-related cell models; Humanin focuses on mitochondrial protection and the inhibition of apoptosis; and MOTS-c centers on regulating mitochondrial energy metabolism to improve cellular energy supply. Although these peptides share common properties—such as protecting cells, resisting oxidative damage, and maintaining connective tissue homeostasis—they differ significantly in their target cells and the molecular pathways they regulate. Researchers can select specific peptides or design multi-group control experiments based on their study objectives to compare the biological effects of these different peptides.

Regarding experimental procedures, Cartalax offers flexible usage; stock solutions at graded concentrations can be prepared according to the experimental protocol and added to cell culture media to initiate treatment. As the prepared peptide solutions have limited stability, it is recommended to prepare them immediately before use; any remaining stock solution should be stored at low temperatures to prevent peptide degradation caused by prolonged exposure to room temperature. When conducting experiments, it is essential to simultaneously set up blank control groups, solvent control groups, and experimental groups with varying concentrations to observe dose-dependent effects and obtain comprehensive, objective data. The raw material is supplied in standard lyophilized vials; small-format samples are suitable for pilot testing, while bulk supplies are available to meet the procurement needs of both small laboratories and large-scale research platforms.

Quality control of raw materials is fundamental to ensuring experimental reproducibility. Cartalax strictly adheres to raw material preparation protocols during production, maintaining rigorous control over the manufacturing environment to minimize contamination by heavy metals, impurity peptides, and microorganisms. Each batch undergoes purity testing via High-Performance Liquid Chromatography (HPLC) alongside assessments for moisture content and microbial limits; a complete Certificate of Analysis (COA) is issued, enabling purchasers to complete material intake verification based on the quality data. A robust quality control system effectively minimizes batch-to-batch variation and reduces experimental interference caused by material inconsistency, making it ideal for research projects requiring high experimental stability.

As the field of peptide research expands, there is steady growth in demand for *in vitro* experiments focusing on extracellular matrix metabolism and the regulation of chondrocyte function. Cartalax has garnered sustained interest from the scientific community due to its ability to modulate chondrocyte activity, promote matrix synthesis, and provide antioxidant protection. This material serves as a high-quality research tool for fundamental studies on chondrocyte metabolic regulation, extracellular matrix homeostasis, and protection against oxidative damage, helping researchers explore the underlying mechanisms governing connective tissue cell homeostasis. Furthermore, the peptide is compatible with various *in vitro* cell culture systems and diverse experimental designs, offering broad potential for application in basic research.

Regarding procurement and delivery, the supplier offers a range of packaging specifications, supporting everything from small research samples to large-volume bulk supplies. Upon order confirmation, materials are shipped in temperature-controlled, protective packaging that shields them from high temperatures and light, ensuring the integrity of the lyophilized powder during transit. In addition to the product itself, supporting documentation—such as physicochemical parameter sheets and quality inspection reports—is provided to facilitate early experimental planning and material intake registration. Customers may also discuss specific packaging requirements or additional testing needs. In summary, as a high-purity synthetic peptide, Cartalax holds unique research value in the field of *in vitro* cellular research. It modulates chondrocyte activity, promotes extracellular matrix synthesis, balances matrix metabolism, scavenges intracellular reactive oxygen species, enhances cellular stress resistance, and maintains connective tissue cell homeostasis; consequently, it is suitable for various *in vitro* research projects focusing on chondrocyte culture, extracellular matrix metabolism, and oxidative damage. Its stable physicochemical properties, rigorous quality assurance, and flexible supply options make it an excellent choice of peptide raw material for these research areas. Researchers can design appropriate *in vitro* experimental protocols tailored to their specific project objectives to deeply investigate the various regulatory effects of Cartalax at the cellular level and further advance research findings regarding matrix-regulating peptides.